Search PubMed⌕ Search

Biomedical subjects

J Oertel

Publications and source records attributed to J Oertel.

54 records · Page 3Linked to original sources
PubMed1983

Alpha naphthyl acetate esterase in human blood cells with different molecular weights.

Normal human blood cells contain esterases which hydrolyze alpha-naphthyl acetate (alpha NA). Purified preparations of these cells were investigated by polyacrylamide gradient gel electrophoresis at pH 9.0 and subsequent staining of gels for esterase activity. Extractable alpha NA esterase was separated according to molecular weight. alpha NA esterase with molecular weight of 55 000 was observed only in lymphocytes and red cells. Lymphocytes from patients with B-cell chronic lymphocytic leukemia (B-CLL) showed alpha NA esterase with molecular weight of 45 000 instead of 55 000. Esterases with molecular weights of 60 000 and 70 000 were detected in granulocytes monocytes and red cells. Only platelets and red cells exhibited alpha NA esterase with molecular weight of 80 000. alpha NA esterases with molecular weight of 290 000 could be demonstrated in granulocytes and red cells. All blood cells contained esterase with molecular weight of 360 000. alpha NA esterase with molecular weight of 390 000 was detected only in red cells. In all blood cells (without lymphocytes) esterase with molecular weight of 500 000 was demonstrated. Only the enzyme in monocytes, granulocytes and red cells was sensitive to fluoride inhibition.

Blood Cells↗
PubMed1983

Dipeptidylaminopeptidase IV (DAP IV) activity in normal and malignant T-cell subsets as defined by monoclonal antibodies.

The activity of dipeptidylaminopeptidase IV (DAP IV) was investigated by a cytochemical method in isolated fractions of normal peripheral blood mononuclear cells and malignant cells from 9 patients with chronic T-cell leukaemia. A positive DAP IV reaction was observed in 52% of normal T cells, a consistent negative reaction in normal B cells and monocytes. 2 distinct T-cell subsets, helper/inducer cells (T4+/T8-) and cytotoxic/suppressor cells (T4-/T8+), were negatively selected by complement-mediated cytolysis utilizing the monoclonal antibodies OKT4 and OKT8. On examination of these T-cell subsets a positive DAP IV reaction was restricted to the majority of normal T4+/T8- cells. The malignant cells from 3 patients with T-chronic lymphocytic leukaemia, expressing the cytotoxic/suppressor phenotype (T4-/T8+) lacked DAP IV activities. In contrast, almost all leukaemic cells from 3 other cases, expressing the helper/inducer phenotype (T4+/T8-), were strongly positive. Despite their T4+/T8- phenotype, the malignant cells from 3 patients with Sézary syndrome were completely DAP IV negative. These findings suggest that the DAP IV reaction may be helpful in the further characterization of normal and malignant T-cell subsets.

Aged↗
PubMed1982

[Serum ferritin in differential diagnosis of anemia (author's transl)].

The concentration of ferritin in the serum of normal males (n = 79) was 98 micrograms/l (geometric mean) with a 95% confidence range of 21-447 micrograms/l. In non-menstruating healthy females (n = 39), the concentration was 85 (26-279) micrograms/l. In menstruating females, serum ferritin was less than 30 micrograms/l only when the duration of menstruation was more than or equal to 4 days. Patients with uncomplicated iron-deficiency anemia had a serum ferritin level less than 20 micrograms/l. After oral or parenteral iron therapy, serum ferritin was greater than 20 micrograms/l in 7 to 17 patients. Serum ferritin was greater than 20 micrograms/l in 8 of 12 patients with a simultaneous inflammatory or malignant disease. Of patients with iron-deficiency anemia, 86% had a serum ferritin level lower than 40 micrograms/l. A serum ferritin level less than 40 micrograms/l was only observed in patients with iron-deficiency anemia and not in patients with other forms of anemia. Of patients with iron-deficiency anemia and a hemoglobin concentration lower than 100 g/l, 80% had a serum iron level less than 13 mumol/l and a total iron binding capacity higher than 70 mumol/l. Anemia of chronic disorders was diagnosed with a sensitivity of 0.93 and a specificity of 0.92 in patients with serum iron less than 13 mumol/l, total iron binding capacity less than 60 mumol/l, erythrocyte sedimentation rate greater than 25 mm in the first hour, and serum fibrinogen greater than 4 g/l. Somewhat better was the same combination except with the serum ferritin level greater than 50 micrograms/l instead of the iron binding capacity. However the predictive value using both combinations was too low.

Anemia, Hypochromic↗
PubMed1982

Localization and characteristics of ferritin in human bone marrow.

It has been found possible to test ferritin concentrations in the reticulum and hemopoietic cells from human bone marrow by an immunoradiometric assay. Ferritin concentration in healthy test persons amounts to 0.92 +/- 0.38 ng/microgram protein in the reticulum and 0.084 +/- 0.031 ng/microgram protein in hemopoietic cells. In healthy test persons about 90% of the ferritin is localized in the reticulum and about 10% in the hemopoietic cells. The ferritin concentration in the reticulum is decreased in patients having iron deficiency anemia. In these patients only 50-70% of the bone marrow ferritin is localized in the reticulum. Bone marrow ferritin was characterized by a combination of anion-exchange chromatography using Sephadex A-50 and an immunoradiometric assay. Marrow ferritin from healthy persons is eluted at chloride concentrations between 200 and 300 mM. The anion-exchange chromatographic properties of ferritin in the reticulum and hemopoietic cells are identical.

Anemia, Hypochromic↗
PubMed1982

[Iron in bone marrow].

In the bone-marrow, non-haemoglobin iron can predominantly be found in the reticulum. Slight granules containing iron can also be observed in parts of erythroblasts by means of the Berlin blue reaction. These cells are called sideroblasts. In chemical respect, non-haemoglobin iron consists of ferritin soluble in water and haemosiderin insoluble in water. Erythroblasts will only take their iron from plasma transferrin. For the most part, this iron uptake is being regulated by erythropoietin adapting erythropoiesis to the oxygen requirements of the tissue. The iron contained in erythroblasts is predominantly utilized for haemoglobin synthesis in these cells. A slight part is being taken up by ferritin. The bone-marrow reticulum will phagocytise aged erythrocytes and store liberated iron as ferritin and haemosiderin. Part of the iron is being delivered again to plasma transferrin. With constant serum iron level the liberation of iron from the reticulo-endothelial tissue must correspond to the iron uptake by erythropoiesis. The absence of iron capable of being coloured in the bone-marrow reticulum is considered to be a reliable parameter of iron deficiency. It enables the diagnosis of iron deficiency anaemia to be made even in those patients with serum iron level and a total iron binding capacity lying within the normal range and no hypochromia of erythrocytes being present. It enables iron deficiency anaemia to be separated from sideropenic anaemia with reticulo-endothelial siderosis in differential-diagnostic manner. Even in patients with sideroblastic anaemia, iron colouring of bone-marrow smears is required for ensuring the diagnosis. Recently, a separation has also been made for idiopathic anaemia with abnormal sideroblasts. In these patients there is an increased risk for acute leukemia to develop.

Anemia, Hypochromic↗
PubMed1981

Germinal center cell lymphomas: prognostic significance of their histopathological differentiation.

Clinical data of 48 patients with centrocytic, 83 patients with centroblastic/centrocytic and 64 patients with centroblastic lymphoma who had entered a prospective multicenter study of the Kiel Lymphoma Study Group since October 1975 were compared. Advanced (stage IV) disease at time of diagnosis, predominantly due to bone marrow infiltration, was most frequent in centrocytic (69% of patients) and in centroblastic/centrocytic (51% of patients) lymphomas as compared to only 28% of patients with centroblastic lymphoma. High survival probability of patients with localized centrocytic and centroblastic/centrocytic lymphomas after radiotherapy, contrasting with a worse prognosis of corresponding patients with centroblastic lymphoma, is compatible with the classification of these lymphoma entities as neoplasias of low-grade malignancy. However, as shown by this prospective and previous retrospective trials overall survival probability of patients with advanced centrocytic lymphoma was inferior to that observed in corresponding patients with centroblastic/centrocytic lymphoma. These findings suggest the possibility that patients with advanced centrocytic lymphoma occupy an intermediate position between typical low-grade and typical high-grade malignant non-Hodgkin lymphomas.

Adult↗
PubMed1981

Clinical and prognostic heterogeneity of non-Hodgkin lymphomas of high-grade malignancy.

Comparison of clinical data of 64 patients with centroblastic lymphoma, 55 patients with immunoblastic lymphoma and 31 patients with lymphoblastic lymphoma not only confirmed the original assumption of high-grade malignancy as proposed by the concept of the Kiel classification but also demonstrated distinct clinical differences, particularly between lymphoblastic lymphoma and the two other entities. Rapid lymph node enlargement as well as steep fall of survival curves within the first year after diagnosis were common characteristics. Bimodal age distribution, predominance of males and early generalization of disease were typical features of lymphoblastic lymphoma; elderly patients and patients with the unclassified subtypes of lymphoblastic lymphoma exhibited the worst prognosis. Whereas patients with centroblastic and immunoblastic lymphomas showed similar distribution of age, sex and initial stage of disease, patients with immunoblastic lymphoma presented more frequently with a reduced performance status and showed a poorer response to radio- and chemotherapy resulting in a worse prognosis discernible after the first year of follow-up. Generalization during course of the disease was significantly more frequent in immunoblastic than in centroblastic lymphoma.

Adolescent↗
PubMed1980

[Chemotherapy of metastasizing colonic carcinomas with nitrosourea compounts. Retrospective analysis].

35 patients with advanced, and previously untreated, colorectal cancer underwent therapy with a combination of 5-fluorouracil, vincristine, DTIC, or one of the nitrosoureas, BCNU or methyl-CCNU, respectively. No complete remission was achieved. 33% of all cases resulted in partial remission and lasted for approximately 3--4 months. Complications were perilous such as neutro- and thrombocytopenia. The overal quality of life was poor. Though several parameters influence these results, we think that the above-listed nitrosoureas do not add substance to the chemotherapy of colorectal cancer.

Adult↗
PubMed1978

Ferritin in bone marrow and serum in iron deficiency and iron overload.

Nonheme iron and ferritin in the bone marrow and serum ferritin was investigated in patients with iron deficiency anaemia or iron overload. As controls served patients without any disturbance of the iron metabolism. There is a precise correlation between the nonheme iron and ferritin in the bone marrow of patients with and without disturbance of iron metabolism. A correlation was also found between the ferritin in the bone marrow and the serum. Nonheme iron and ferritin in the bone marrow and serum ferritin was decreased in patients with iron deficiency anaemia. Conversely, the same parameters were increased in patients with iron overload.

Anemia, Hypochromic↗
PubMed1977

[Serumferritin in patients with malignant lymphomas (author's transl)].

Serum of 70 patients with malignant lymphoma was tested for concentration of ferritin by immunoradiometric assay. Serum of patients with Hodgkin's disease showed an apparently increased ferritin concentration only in the stage III and IV. Concentration of serum ferritin was found normal in patients with chronic lymphocytic leukemia and non-Hodgkin's lymphoma of low malignancy. Among patients with non-Hodgkin's lymphome of high malignancy only one who suffered from advanced immunoblastic sarcoma showed increased concentration of serum ferritin. Patients with elevated concentration of serum ferritin had a decreased level of serum iron and showed also anemia. Their bone marrow reticulum was rich in dyeing iron. These results suggest that hyperferritinemia in patients with advanced Hodgkin's disease is related to a lack of release of iron from reticuloendothelial system.

Bone Marrow↗
PubMed1977

[Serum ferritin in iron deficiency anaemia (author's transl)].

Red cell indices, plasma iron, total iron-binding capacity and serum ferritin levels were measured in 73 patients with iron deficiency anaemia. There was decreased plasma iron and MCHC with an increased total iron-binding capacity in 38 patients (type I iron deficiency anaemia). There was no hypochromia in 18 patients with decreased plasma iron and normal total iron-binding capacity; haemoglobin concentration was higher than 90 g/l (type II). Normal MCHC, plasma iron and total iron-binding capacity were found in 17 patients with haemoglobin values higher than 105 g/l (type III). Serum ferritin measurements were made by the immunoradiometric assay. The ferritin concentration was less than 40 micron/l in 66 patients with iron deficiency anaemia. The test proved reliable in diagnosing mild iron deficiency anaemia (types II and III) without bone marrow aspiration.

Anemia, Hypochromic↗
PubMed1976

[Significance of metabolic parameters in Hodgkin's disease (author's transl)].

In 56 patients with Hodgkin's disease, the following bloodtests were carried out: erythrocyte sedimentation rate (ESR), fibrinogen, alpha2-globuline, serium iron concentrations and alkaline phosphatase activity. In some patients we additionally measured alkaline leucocyte phosphatase and serum ribonuclease activity. In our series ESR, serum iron and alpha2-globuline concentrations were the most sensitive metabolic parameters. A rise in fibrinogen concentration, alkaline phosphatase and serum ribonclease activity seems to indicate extensive disease. It is not possible, however, to discern between a state of remission and stage I by means of these parameters. ESR, serum iron and alpha2-globuline concentrations might be either elevated or normal in both instances. These parameters seem important in order to distinguish between a remission or stage I on the one hand and extensive disease in stage III and IV on the other hand. Concomitant findings of ESR above 40 mmh, elevated concentrations of fibrinogen and alpha2-globuline, as well as elevated alkaline phosphatase and serum and serum ribonuclease activity mostly indicate stage III or IV.

Alkaline Phosphatase↗
PubMed1976

Effects of kidney extract on the folic acid induced proliferation of the rat kidney.

Single injection of a high dose of folic acid causes a proliferation of the kidney with an increase of the 3H-thymidine incorporation into the DNA of kidney cortex slices in rats. An aqueous extract from rat kidneys inhibits the increase of 3H-thymidine incorporation. The inhibition begins after 4 hours. The maximum effect is observed between 11 and 17 hours after injection of the kidney extract. The kidney extract also inhibits the increase of the DNA content per kidney after folic acid injection. Heart, lung, spleen and liver extracts and bovine serum albumin do not lead to inhibition of the 3H-thymidine incorporation into the DNA of kidney cortex sclices.

Animals↗
PubMedDate not supplied

Expression of multidrug transporters in dysembryoplastic neuroepithelial tumors causing intractable epilepsy.

OBJECTIVE: Dysembryoplastic neuroepithelial tumors (DNT) are relatively benign brain lesions that often cause medically intractable epilepsy. There is mounting evidence that multidrug transporters such as P-glycoprotein (P-gp) or multidrug resistance-associated proteins (MRP) play an important role in the development of resistance to antiepileptic drugs (AED). MATERIAL AND METHODS: In the present study, we examined the expression of several multidrug transporters in 14 cases of DNT. The peritumoral brain tissue as well as 9 cases of arteriovenous malformations (AVM) served as controls. P-gp, MRP2, MRP5 and breast cancer resistance protein (BCRP) expression was evaluated qualitatively and quantitatively using immunohistochemistry. RESULTS: All transporters were overexpressed quantitatively in DNT, but each revealed a different labeling pattern. P-gp and BCRP were predominantly located in the endothelium of brain vessels. MRP5 was detected primarily in endothelial cells, but notably also in neurons. The expression of P-gp, MRP2 and MRP5 was low in AVM, whereas BCRP demonstrated strong staining. Examination of MDR1 gene polymorphisms revealed no correlation with P-gp expression whereas the MRP2 exon 10 G1249A polymorphism was associated with different MRP2 labelling. CONCLUSIONS: Our results show that multidrug transporters are overexpressed in DNT. This finding supports the view that several of these transport proteins may play an important role in the mechanisms of drug resistance in epileptic brain tissue.

Adolescent↗
PubMedDate not supplied

Cytologic and immunocytologic studies of peripheral T-cell lymphomas.

Lymph node aspirates from 18 peripheral T-cell lymphomas (PTLs) were analyzed. Cytologic and immunocytologic studies were performed on Cytospin preparations using the alkaline phosphatase-antialkaline phosphatase method with a panel of monoclonal antibodies (CD3, CD4, CD8, CD19 and CD30). The cytologic diagnosis was confirmed by histologic investigation. Nine lymph node aspirates from patients with Lennert's lymphoma, angioimmunoblastic (AILD)-type PTL and pleomorphic small-cell-type PTL were composed predominantly of small-to-intermediate-sized lymphocytes. An admixture of plasma cells, eosinophils, neutrophils, lymphocytes with an irregular nucleus, granula in the cytoplasm or abundant cytoplasm was also seen. Nine lymph node aspirates from patients with T-immunoblastic lymphoma, pleomorphic large-cell-type PTL and large-cell anaplastic (Ki-1+) lymphoma showed marked cytologic heterogeneity. Immunocytologic investigation of the aspirates using the antibodies CD3, CD4, CD8, CD19 and CD30 was helpful for the differentiation of PTLs from reactive lymphadenopathy and other malignant lymphomas. A strong predominance of CD3+ cells was found in only seven cases. The aspirates expressed a helper/inducer phenotype in 11 cases and a suppressor/cytotoxic phenotype in 4 cases. A T-cell phenotype not corresponding to the normal T-cell phenotype was found in nine cases. In 15 of the 18 cases, the number of CD19+ cells was found to be less than 15%. The large cells of the large-cell anaplastic (Ki-1+) lymphoma expressed the antigens CD30 and CD45 and were negative for CD15. These findings indicate that immunocytologic studies can be used in improving the cytologic diagnosis of PTLs.

Antibodies, Monoclonal↗